FDA Investigator Scott A Golladay

Scott A Golladay has conducted inspections on 31 sites in 3 countries as of 09 Mar 2020. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
31
Last Inspection Date:
09 Mar 2020
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America, Switzerland, Germany
FDA Investigators that have inspected at least one site in common with Scott A Golladay:
Aaron L Dunbar, Aimee J Edwin, Alan L Truong, Althea A Williams, Ana M Placencia, Andrew A Hoopes, Anthony J Ladner, Anthony R Bucks, April L Brown, April L Young, Ashley A Mutawakkil, Azza Talaat, Beatrix D Arevalo, Beatrix D Hippe, Billi Jom Johnson, Bo Chi, PhD, Bradley A Servais, Brentley S Collins, Brett R Havranek, Brittany D Terhar, Carl A Huffman, III, Catherine V Quinlan, Charles I Ann, Charles R Cote, RIC, Christian D Lynch (CDL), Christina L Bigham, Christine A Harman, PhD, Cody D Rickman, Constance L Richard, Corey K Reno, Courtney R Ingalsbe, Courtney R Tiegs, Dacia E Quick, Dale A Nyberg, Damaris Y Hernandez, Danial S Hutchison, Daniel J Brown, Darren S Morgan, David B Wieneke, David J Eide, David J Gasparovich, David J Ward, Dawn C Olenjack, Denise L Burosh, Denise M Digiulio, Dolores Harper, Donald L Myers, Duc Minh H Nguyen, Edward M James, Eliezar Ramos, Emily J Orban, Eric Hales, PhD, Eric L Dong, BS, Eric M Mueller, PharmD, Eric M Padgett, Eric S Myskowski, Fannie M Harrell, Gene D Arcy, Geneve M Maxwell, Geneve M Parks, Greg A Abel, Gregory A Berg, Gregory S Larson, Gregory W Smith, Gwyn G Dickinson, Hector A Carrero, Helen B Ricalde, Helen Y Saccone, Howard A Burmester, Ivan E Reyes, Jacob G Lutz, Jacqueline Mdiaz Albertini, James A Beaulieu, James I Giefer, James K Ireland, Jane E Nelson, Janet B Abt, Janet L Bowen, Janis R Armedoriz, Jasjeet K Sekhon, Jazmine N Still, Jeffery A Hangartner, Jeffrey A Sommers, Jeffrey D Meng, Jeffry A Bernhardt, Jennifer A Longie Vollom, Jennifer Al Vollon, Jennifer S Ness, Jesse P Romenesko, John E Emmert, Jonathan G Swoboda, Joseph D Gong, Joseph M Edwin, Joseph R Lambert, Justin A Boyd, Justin J Jafferis, Karen M Labounty, Karla J Youngberg, Kellie L Thommes, RN, Kellie L Westerbuhr, Kelly K Nachtigal, Ken L Bowers, Kevin A Swiss, PhD, Kevin D Kallander, Kevin P Regan, Kibily D Dembele, Kristen Nickens, PhD, Kristy E Zuroski, Kyle J Mccracken, Lauren E Sanger, Leslie A Paul, Lewis K Antwi, Lindsey M Schwierjohann, Lisa L Flores, M Edith Snyder, Margaret A Smithers, Maria E Treadwell, Marie A Fadden, Marissa S Steinhagen, Martha Sullivan Myrick, Matthew B Casale, Matthew J Gretkierewicz, Matthew M Schuckmann, Matthew R Sleeter, Melissa D Kalik, Melissa I Michurski, Michele L Forster, PhD, Michele L Obert, Michele Perry Williams, Mihaly S Ligmond, Monica M Mcclure, Msdap Gonzlezk, Myra K Casey, Nancy G Schmidt, Nibin Varghese, MS, Nicole C Victoria, PhD, Nicole E Knowlton, Omotunde O Osunsanmi, Patricia A Holmstrom, Patsy J Domingo, Paula A Trost, Philip A Klimkewicz, Prabhu P Raju, Ralph A Erickson, Ralph H Vocque, Ralph Jerndal, Ralph W Jemdal, Raymond R Roy, PhD, Rebecca E Dombrowski, Richard L Rutherford, Rita K Kabaso, Robert C Coleman, Robert J Ham, Robert M Barbosa, Robert R Barbosa, Ronald G Crawford, Ross J Grigsby, Sana A Elassar, Sandra A Hughes, Sandra Sejdinovic, Sanket N Patel, Sarah A Palmer, Sarah E Rhoades, Sarah M Napier, Sarah Rhoades, Scott B Laufenberg, Shafiq S Ahadi, Sharon K Thoma, PharmD, Sharon L Matson, Shirley J Berryman, Sidney B Priesmeyer, Simone E Pitts, Soyinka S Eneng, Steven D Kehoe, Steven P Donald, Susan M Atcher, Susan M Jackson, Susan M Matthias, Susan P Bruederle, Susanna E Ford, Tara L Breckenridge, Tara L Greene, Thomas A Peter, Thomas J Cosgrove, Timothy R Marrs, Tonnie L Carter, Toyin B Oladimeji, Tracey Asinjen Wiersma, Victoria L Palmer, Walsworth, William D Tingley, William E Keer, Yiyue Zhang (nmi), PhD, Yoon K Oh, Zi Qiang Gu

Scott A Golladay's Documents

Publish Date Document Type Title
March, 2020 FDA 483 3M Company - Form 483, 2020-03-20
September, 2018 EIR Pharmacia & Upjohn Company LLC - EIR, 2018-12-10
May, 2018 FDA 483 3M Company - Form 483, 2018-05-25
July, 2017 FDA 483 Padagis US LLC - Form 483, 2017-07-07
February, 2019 FDA 483 Response Lifecore Biomedical, LLC - Form 483R, 2019-02-26
December, 2018 FDA 483 Upsher-Smith Laboratories, LLC - Form 483, 2018-12-19
February, 2018 FDA 483 Pace Analytical Life Sciences,LLC - Form 483, 2018-02-07
September, 2016 FDA 483 Response Entellus Medical - Form 483R, 2016-10-12
November, 2019 EIR Lifecore Biomedical, LLC - EIR, 2019-11-22
June, 2019 FDA 483 Northland Nuclear Medicine, LLC - Form 483, 2019-06-07
February, 2017 FDA 483 Lifecore Biomedical - Form 483, 2017-02-22
September, 2016 FDA 483 Entellus Medical - Form 483, 2016-09-27
September, 2018 FDA 483 Response SV Labs Prescott Corporation - Form 483R, 2018-10-16
January, 2020 EIR Hospira, Inc. - EIR, 2020-01-17
September, 2018 FDA 483 Pharmacia & Upjohn Company LLC - Form 483, 2018-09-21
July, 2016 FDA 483 Peter Karachunski, M.D. - Form 483, 2016-07-16
September, 2018 EIR Pharmacia & Upjohn Company LLC - EIR, 2018-09-21
January, 2020 FDA 483 Response Hospira, Inc. - Form 483R, 2020-02-10
September, 2018 FDA 483 SV Labs Prescott Corporation - Form 483, 2018-09-28
July, 2017 EIR Padagis US LLC - EIR, 2017-07-07
May, 2019 FDA 483 Pharmaceutical Specialties, Inc. - Form 483, 2019-05-03
January, 2020 FDA 483 Hospira, Inc. - Form 483, 2020-01-17
March, 2020 FDA 483 Takeda Pharmaceuticals U.S.A., Inc. - Form 483, 2020-03-18
February, 2019 FDA 483 Lifecore Biomedical, LLC - Form 483, 2019-03-22
February, 2018 FDA 483 Response Pace Analytical Life Sciences,LLC - Form 483R, 2018-02-23
November, 2016 EIR SAFC Inc - EIR, 2016-11-04
December, 2018 FDA 483 Upsher-Smith Laboratories, LLC - Form 483, 2018-12-19
February, 2019 EIR Lifecore Biomedical, LLC - EIR, 2019-02-26

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more